Literature DB >> 6176686

Cortical substance P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type.

H A Crystal, P Davies.   

Abstract

The concentration of substance P-like immunoreactive material (SPLI) and somatostatin-like immunoreactive material (SLI) and the activity of acetyl-CoA: choline-O-acetyltransferase (ChAT; EC 2.3.1.6) were measured in eight brain regions of 13 normal patients and 12 patients with Alzheimer disease/senile dementia of the Alzheimer type (AD/SDAT). SPLI was significantly lower in five of eight regions in the patients with AD/SDAT. Younger patients with AD/SDAT had significantly lower SLI in the parietal cortex than older patients. ChAT activity and SPLI in the parietal cortex of the presenile patients with AD/SDAT were not significantly different from values found in older patients.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6176686     DOI： 10.1111/j.1471-4159.1982.tb06665.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN： 0022-3042            Impact factor:   5.372


  9 in total

1.  Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain.

Authors:  K Toide; T Fujiwara; Y Iwamoto; M Shinoda; K Okamiya; T Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

Review 2.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

3.  An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P.

Authors:  N W Kowall; M F Beal; J Busciglio; L K Duffy; B A Yankner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

4.  Distribution of GABA and neuropeptides in the human cerebral cortex. A light and electron microscopic study.

Authors:  W Y Ong; L J Garey
Journal:  Anat Embryol (Berl)       Date:  1991

5.  Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.

Authors:  P Morain; J L Robin; G De Nanteuil; R Jochemsen; V Heidet; D Guez
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 6.  The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.

Authors:  Nick Pantaleo; Wayne Chadwick; Sung-Soo Park; Liyun Wang; Yu Zhou; Bronwen Martin; Stuart Maudsley
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

7.  Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals.

Authors:  Pavel Katsel; Weilun Tan; Vahram Haroutunian
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

8.  Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

Authors:  H Cramer; D Schaudt; K Rissler; D Strubel; J M Warter; F Kuntzmann
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

9.  An increase in sensitivity of rat cingulate cortical neurones to substance P occurs following withdrawal of chronic administration of antidepressant drugs.

Authors:  R S Jones; H R Olpe
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.